Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Conditions
Interventions
Eluxadoline
Placebo
Locations
283
United States
Furiex Research Site
Athens, Alabama, United States
Furiex Research Site
Birmingham, Alabama, United States
Furiex Research Site
Foley, Alabama, United States
Furiex Research Site
Huntsville, Alabama, United States
Furiex Research Site
Ozark, Alabama, United States
Furiex Research Site
Chandler, Arizona, United States
Start Date
May 29, 2012
Primary Completion Date
July 29, 2014
Completion Date
July 29, 2014
Last Updated
September 4, 2018
NCT07481422
NCT05740319
NCT05730491
NCT07089420
NCT06866106
NCT05293769
Lead Sponsor
Furiex Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions